<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925143</url>
  </required_header>
  <id_info>
    <org_study_id>JLT-NM5</org_study_id>
    <nct_id>NCT02925143</nct_id>
  </id_info>
  <brief_title>Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning</brief_title>
  <acronym>INVERT</acronym>
  <official_title>Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning - a Multicenter Interrupted Time Series Study (INVERT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of an e-learning course in neuromuscular monitoring on the frequency of&#xD;
      application of objective neuromuscular monitoring for assessment of depth of neuromuscular&#xD;
      blockade in general anaesthesia and secondarily on the incidence of residual neuromuscular&#xD;
      blockade after anesthesia.&#xD;
&#xD;
      We will collect data prospectively from 6 Danish anaesthesia departments from the time of&#xD;
      intervention, using data from the Anaesthesia Information Management System (AIMS). Baseline&#xD;
      data is obtained from another study based on the same data extraction procedure&#xD;
      (NCT02914119).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
    <description>Number of Participants Who Received a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing NMBA (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
    <description>Number of Participants Who Received a Non-depolarizing Neuromuscular Blocking Agent (NMBA) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA</measure>
    <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours]</time_frame>
    <description>The Train-of-four (TOF) ratio is the ratio of the fourth to the first muscle response after 4 stimuli at the ulnar nerve at the wrist at 2 Hz. The response is measured using acceleromyography. If the last measurement is performed before return of any muscle function, the ration can not be given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
    <description>If the total dose of sugammadex in the anaesthesia information management system is &gt; 0, the outcome is &quot;yes&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
    <description>If the total dose of neostigmine in the anaesthesia information management system is &gt; 0, the outcome is &quot;yes&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of More Than One Reversal Agent in Cases Receiving a Non-depolarizing NMBA (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
    <description>If the total dose of neostigmine is bigger than (&gt;) the first dose administered, the outcome is &quot;yes&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6525</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>E-learning course</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-learning course in neuromuscular monitoring</intervention_name>
    <description>An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
    <arm_group_label>E-learning course</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Departments We will include the 6 largest anaesthesia departments in the Zealand&#xD;
        Region of Denmark.&#xD;
&#xD;
        Anaesthetists We will include the following anaesthesia personnel as anaesthetists: nurse&#xD;
        anaesthetists in training, nurse anaesthetists, first year residents in anaesthesiology,&#xD;
        residents in the last 4 years of training in anaesthesiology, and specialist consultants in&#xD;
        anaesthesia.&#xD;
&#xD;
        Patients We will include and collect data from all patients undergoing general anaesthesia&#xD;
        with neuromuscular blockade in each data collection period. Patients, who are eligible more&#xD;
        than once, i.e. undergoing general anaesthesia on more than one occasion, will be included&#xD;
        in the analyses with a case for every general anaesthetic received.&#xD;
&#xD;
        Exclusion criteria We will exclude personnel without clinical functions, i.e.&#xD;
        administrative personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob L Thomsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sponsor principal investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <results_first_submitted>March 24, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Jakob Louis Thomsen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Residual nerve blockade</keyword>
  <keyword>Neuromuscular monitoring</keyword>
  <keyword>Residual curarization</keyword>
  <keyword>Neuromuscular blocking agents</keyword>
  <keyword>E-learning</keyword>
  <keyword>Web based learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing of data not included in the permissions granted by authorities stated below</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02925143/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>E-learning Course</title>
          <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Receiving Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine)</title>
              <participants_list>
                <participants group_id="P1" count="3099"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Receiving Non-depolarizing Neuromuscular Blocking Agent (NMBA)</title>
              <participants_list>
                <participants group_id="P1" count="3426"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>E-learning Course</title>
          <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6525"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3597"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no)</title>
        <description>Number of Participants Who Received a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.</description>
        <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
        <population>Only patients who received a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) are analyzed in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no)</title>
          <description>Number of Participants Who Received a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.</description>
          <population>Only patients who received a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) are analyzed in this outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3099"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
        <description>Number of Participants Who Received a Non-depolarizing Neuromuscular Blocking Agent (NMBA) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.</description>
        <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
        <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
          <description>Number of Participants Who Received a Non-depolarizing Neuromuscular Blocking Agent (NMBA) and was Monitored with Objective Neuromuscular Monitoring (Acceleromyography). Data on neuromuscular monitoring is automatically registered in the electronic patient chart when the equipment for acceleromyography is activated.</description>
          <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA</title>
        <description>The Train-of-four (TOF) ratio is the ratio of the fourth to the first muscle response after 4 stimuli at the ulnar nerve at the wrist at 2 Hz. The response is measured using acceleromyography. If the last measurement is performed before return of any muscle function, the ration can not be given.</description>
        <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours]</time_frame>
        <population>Only patients receiving a non-depolarizing neuromuscular blocking agent, monitored with acceleromyography and with a valid TOF ratio in the last three measurements are included in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA</title>
          <description>The Train-of-four (TOF) ratio is the ratio of the fourth to the first muscle response after 4 stimuli at the ulnar nerve at the wrist at 2 Hz. The response is measured using acceleromyography. If the last measurement is performed before return of any muscle function, the ration can not be given.</description>
          <population>Only patients receiving a non-depolarizing neuromuscular blocking agent, monitored with acceleromyography and with a valid TOF ratio in the last three measurements are included in this outcome.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3027"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.23" spread="29.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
        <description>If the total dose of sugammadex in the anaesthesia information management system is &gt; 0, the outcome is &quot;yes&quot;.</description>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
        <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
          <description>If the total dose of sugammadex in the anaesthesia information management system is &gt; 0, the outcome is &quot;yes&quot;.</description>
          <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
        <description>If the total dose of neostigmine in the anaesthesia information management system is &gt; 0, the outcome is &quot;yes&quot;.</description>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
        <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
          <description>If the total dose of neostigmine in the anaesthesia information management system is &gt; 0, the outcome is &quot;yes&quot;.</description>
          <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Administration of More Than One Reversal Agent in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
        <description>If the total dose of neostigmine is bigger than (&gt;) the first dose administered, the outcome is &quot;yes&quot;.</description>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
        <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Administration of More Than One Reversal Agent in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
          <description>If the total dose of neostigmine is bigger than (&gt;) the first dose administered, the outcome is &quot;yes&quot;.</description>
          <population>Only patients receiving a non-depolarizing neuromuscular blocking agent are analyzed in this outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA</title>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes</time_frame>
        <population>Only patients receiving a non-depolarizing neuromuscular blocking agent with data on length-of-stay in the post-anaesthesia care unit are analyzed in this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>E-learning Course</title>
            <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA</title>
          <population>Only patients receiving a non-depolarizing neuromuscular blocking agent with data on length-of-stay in the post-anaesthesia care unit are analyzed in this outcome.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="1" upper_limit="1431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>E-learning Course</title>
          <description>E-learning course in neuromuscular monitoring: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6525"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jakob Thomsen</name_or_title>
      <organization>Herlev Hospital</organization>
      <phone>004538683868</phone>
      <email>dr.j@demants.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

